Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and ¹⁸F-FMISO PET.

ABSTRACT: Tumoral hypoxia correlates with worse outcomes in glioblastoma (GBM). While bevacizumab is routinely used to treat recurrent GBM, it may exacerbate hypoxia. Evofosfamide is a hypoxia-targeting prodrug being tested for recurrent GBM. To characterize resistance to bevacizumab and identify those with recurrent GBM who may benefit from evofosfamide, we ascertained MRI features and hypoxia in patients with GBM progression receiving both agents. Thirty-three patients with recurrent GBM refractory to bevacizumab were enrolled. Patients underwent MR and ¹⁸F-FMISO PET imaging at baseline and 28 days. Tumor volumes were determined, MRI and ¹⁸F-FMISO PET-derived parameters calculated, and Spearman correlations between parameters assessed. Progression-free survival decreased sign

SUBMITTER: Huang S 

PROVIDER: S-EPMC8027395 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature